Advertisement

Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla

  • Zhao Bi
  • Jingjing Liu
  • Peng Chen
  • Yanbing Liu
  • Tong Zhao
  • Chunjian Wang
  • Zhaopeng Zhang
  • Xiao Sun
  • Pengfei Qiu
  • Binbin Cong
  • Xianrang Song
  • Yongsheng WangEmail author
Original Article
  • 53 Downloads

Abstract

Purpose

This study aims to determine the optimal time to perform sentinel lymph node biopsy (SLNB) for patients with clinically node-negative (cN0) disease following neoadjuvant chemotherapy (NAC).

Method

From April 2008 to April 2018, 592 patients with breast cancer underwent after NAC were included in this study. Patients with cN0 before and ycN0 disease after NAC received SLNB and axillary lymph node dissection (ALND) in case of positive sentinel lymph nodes (SLNs). For patients with clinically node-positive (cN+) disease, the axillary surgery is based on the doctor’s decision.

Result

In general, 17.6% (104/592) of patients achieved total pathologic complete response (pCR), which was 6.9%, 33.3%, 32.3% and 15.3%, respectively, among patients with hormone receptor (HR) positive/ human epidermal growth factor receptor-2 (HER-2) negative (HR+/HER2−) subtype, triple-negative (TN) subtype, HER-2 positive (HER2+) subtype with and without targeted therapy (p < 0.001). Among the 525 cN+ patients, the axillary nodal pCR (apCR) rate was 34.5%, and the apCR rate was significantly higher in patients with HER2+ (58.6% with and 28.2% without targeted therapy respectively) and TN subtype (53.2%) than that in patients with HR+/HER2−subtype (21.2%, p < 0.001). Among the 67 cN0 patients, the positive rate of SLNs was 19.4% (13/67), which was 28.1% (9/32), 13.3% (2/15) and 10.0% (2/20), respectively, among patients with HR+/HER2−, TN and HER2 + subtypes.

Conclusion

The pCR rates were significantly related to molecular subtype. Combining the apCR rates in different molecular subtypes of cN+ patients and the excellent locoregional control of AOSOG Z0011 and AMAROS trials in cN0 patients, it would be preferable to perform SLNB prior to NAC for cN0 patients with HR+/HER2− subtype, and SLNB after NAC for those cN0 patients with TN and HER2+ subtype to increase the chance of avoiding ALND. Among cN0 patients, TN and HER2 + subtypes would benefit more from axillary de-escalating surgery after NAC than HR+/HER2− subtype.

Keywords

Breast cancer Neoadjuvant chemotherapy Molecular subtype Pathologic complete response Sentinel lymph node biopsy 

Notes

Acknowledgements

This work was supported by National Natural Science Foundation of China (81502314) and Medical and Health Science Technology Development Program in Shandong Province (2015WS0151).

Compliance with ethical standards

Conflict of interest

The authors have stated that they have no conflicts of interest in this work.

References

  1. 1.
    Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483–93.CrossRefPubMedGoogle Scholar
  2. 2.
    Lori F, George P, Emily C, et al. Tumor biology predicts pathologic complete response to neoadjuvant chemotherapy in patients presenting with locally advanced breast cancer. Ann Surg Oncol. 2017;34(13):3896–902.Google Scholar
  3. 3.
    Kumar A, Puri R, Gadgil PV, et al. Sentinel lymph node biopsy in primary breast cancer: window to management of the axilla. World J Surg. 2012;36(7):1453–1459.CrossRefPubMedGoogle Scholar
  4. 4.
    Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg. 2014;260(4):608–16.CrossRefPubMedGoogle Scholar
  5. 5.
    Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SNFNAC study. J Clin Oncol. 2015;33(3):258–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Mamtani A, Andrea V, Tari A, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study[J]. Ann Surg Oncol. 2016;23(11):3467–74.CrossRefPubMedGoogle Scholar
  7. 7.
    Diego E, Mcauliffe P, Soran A, et al. Axillary staging after neoadjuvant chemotherapy for breast cancer: a pilot study combining sentinel lymph node biopsy with radioactive seed localization of pretreatment positive axillary lymph nodes. Ann Surg Oncol. 2016;23(5):1549–53.CrossRefPubMedGoogle Scholar
  8. 8.
    Judy C, Linda M, Karla V, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg. 2014;260(4):608–16.CrossRefGoogle Scholar
  9. 9.
    Bill L, Krishnamurti U, Shristi B, et al. Biomarkers predicting pathological complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol. 2016;0:1–8.Google Scholar
  10. 10.
    Audree B, Wei T, Savitri K, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA. 2017;152(7):665–70.Google Scholar
  11. 11.
    Grasishar WJ, Anderson BO, Abraham J, et al. Breast cancer, Version 2. 2018 Featured Updates to the NCCN Guidelines. National Comprehensive Cancer Network. Available at: http://www.NCCN.org. Accessed 5 Oct 2018.
  12. 12.
    Curigliano G, Burstein H, Winer E, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2017;28: 1700–1712.CrossRefPubMedGoogle Scholar
  13. 13.
    Pilewskie M, Zabor E, Mamtani A, et al. The optimal treatment plan to avoid axillary lymph node dissection in early-stage breast cancer patients differs by surgical strategy and tumor subtype. Ann Surg Oncol. 2017;24(12):3527–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.CrossRefPubMedGoogle Scholar
  15. 15.
    Mila D, Geertjan T, Marieke ES, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS):a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.CrossRefGoogle Scholar
  16. 16.
    Krag DN, Anderson SJ, Julian TB. et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010; 11 (10): 908–909.CrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2019

Authors and Affiliations

  • Zhao Bi
    • 1
    • 2
  • Jingjing Liu
    • 3
  • Peng Chen
    • 2
  • Yanbing Liu
    • 2
  • Tong Zhao
    • 2
  • Chunjian Wang
    • 2
  • Zhaopeng Zhang
    • 2
  • Xiao Sun
    • 2
  • Pengfei Qiu
    • 2
  • Binbin Cong
    • 1
    • 2
  • Xianrang Song
    • 2
  • Yongsheng Wang
    • 2
    Email author
  1. 1.School of Medicine and Life SciencesUniversity of Jinan-Shandong Academy of Medical SciencesJinanPeople’s Republic of China
  2. 2.Breast Cancer CenterShandong Cancer Hospital Affiliated to Shandong UniversityJinanPeople’s Republic of China
  3. 3.LaboratoryQingdao Municipal HospitalQingdaoPeople’s Republic of China

Personalised recommendations